Navigation Links
Taiho Pharmaceutical Announces Results of Randomized Phase II Clinical Trial with Novel Antitumor Agent TAS-102
Date:7/22/2011

TOKYO, July 22, 2011 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Toru Usami) announced on July 22 the results of a randomized, Phase II clinical trial for the novel oral nucleoside antitumor agent TAS-102 under development by the company for metastatic colorectal cancer, at the 9th Annual Meeting of the Japanese Society of Medical Oncology held in Yokohama. (Abstract no. 10428)

The trial was a randomized, double-blind, placebo-controlled study with a primary outcome measure of overall survival involving 172 patients with refractory metastatic colorectal cancer who had received standard chemotherapy at least two or more regimens containing a fluoropyrimidine, irinotecan, and oxaliplatin. The results indicated that the TAS-102 significantly improved overall survival compared with the placebo (overall survival median: 9.0 months vs. 6.6 months) and significantly reduced the risk of mortality (HR=0.56, p=0.0011). Also, no instances of treatment-related mortality were reported. The most frequently reported adverse drug reaction with a CTCAE grade 3 or higher was neutropenia. Grade 3 or higher diarrhea, fatigue, nausea, and other adverse reactions were no more than 10%.

In light of these results, Taiho Pharmaceutical will proceed with global development of TAS-102 so that this drug can be offered as soon as possible to metastatic colorectal cancer patients who have exhausted proven treatment options and there remains a high unmet medical need.

About TAS-102:

TAS-102 is a novel oral nucleoside antitumor agent with a novel mechanism of action, composed of a mixture of Trifluorothymidine (FTD), which demonstrates antitumor effects through incorporation into DNA, and 5-chloro-6-(2-iminopyrrolidin-1-yl)-methyl-2,4(1H,3H)-pyrimidinedione hydrochloride (TPI), which inhibits the degradation of FTD. Phase I trials began in Japan in 2005, and the drug continues to be developed as a treatment for colorectal cancer refra
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014 Pharmaceutical Care Management ... today outlined policy solutions that could reduce prescription fraud ... Hill briefing, " Prescription Opioid Abuse: Fighting Back on ... Reform and PCMA. The briefing featured ... prescription drug abuse and fraud. The Centers for Disease ...
(Date:9/29/2014)... , Sept. 29, 2014 EU5 Sigmoidoscopes ... new report, "EU5 Sigmoidoscopes Market Outlook to 2020", ... market. The report provides value, in millions of ... (in US dollars) within market segments - Flexible ... and Flexible Non-Video (Fibre) Sigmoidoscopes). The ...
(Date:9/29/2014)... SAN DIEGO , 29 de septiembre de 2014 ... adelante, Daiichi Sankyo) (TSE: 4568) y Ambit Biosciences (NASDAQ: ... que han llegado a un acuerdo de fusión definitivo ... acciones ordinarias de Ambit Biosciences a un precio de ... una oferta de licitación seguida de una fusión con ...
Breaking Medicine Technology:PCMA: How Congress Can Fight Prescription Drug Fraud and Abuse 2EU5 Sigmoidoscopes Market Outlook to 2020 2EU5 Sigmoidoscopes Market Outlook to 2020 3Daiichi Sankyo adquiere Ambit Biosciences 2Daiichi Sankyo adquiere Ambit Biosciences 3Daiichi Sankyo adquiere Ambit Biosciences 4Daiichi Sankyo adquiere Ambit Biosciences 5Daiichi Sankyo adquiere Ambit Biosciences 6Daiichi Sankyo adquiere Ambit Biosciences 7Daiichi Sankyo adquiere Ambit Biosciences 8
... safety profile of BSI-201 in ... subjects with advanced solid tumors -, BRISBANE, Calif., ... developing novel cancer therapies,today announced that data supporting its lead ... of Clinical Oncology annual,meeting in Chicago., Findings will be ...
... SGP ), a leader in advancing the ... infection, announced today that data from,several clinical studies ... therapy, as well as boceprevir, the,company,s investigational oral ... annual Digestive Disease Week (DDW) meeting to be ...
Cached Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7
(Date:9/30/2014)... Timber Home Living Magazine is documenting each ... family’s reclaimed Douglas fir timber frame home in Austerlitz, NY. ... architectural planning, to the frame raising, to enclosure, to completion. ... Works, after following the timber framing company for years in ... vacation home on land they fell in love with over ...
(Date:9/30/2014)... 2014 An estimated 40 million people ... years, profoundly impacting health plans’ business models. Atlantic Information ... virtual conference, “Private Insurance Exchanges: Bottom-Line Strategies for ... where private health insurance exchanges are today, where they ... look like when they get there. , During this ...
(Date:9/30/2014)... DC (PRWEB) September 30, ... **MEDIA ADVISORY** , From:        Hope ... Barnwell, 910.554.1505, abarnwell(at)hopeforthewarriors(dot)org ... Hope® Celebration , Date:        Thursday, ... Address:    The Army and Navy ...
(Date:9/30/2014)... Boardman, Ohio (PRWEB) September 30, 2014 If ... qualities of a leader, what would it say? Would you ... Although it might be tempting to create a leadership “wish ... types of people, so too are there different types of ... how can companies create leadership development programs that account for ...
(Date:9/30/2014)... Williamson shares her life story for the first time ... Sex and Commitment" . As co-founder with her husband ... and controversial Sandstone Retreat in Malibu, California, in the ... became known as the hub of the sexual revolution. ... with a membership reaching 500 and nearly 8,000 visitors. ...
Breaking Medicine News(10 mins):Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 2Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 3Health News:New Atlantic Information Services Virtual Conference Will Detail Private Exchange Strategies for Health Plans 2Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2Health News:Personality Plays a Key Role in Leadership Development 2Health News:Personality Plays a Key Role in Leadership Development 3Health News:The Autobiography "An Extraordinary Life: Love, Sex and Commitment" Embraces Healthy Sexual Behavior 2Health News:The Autobiography "An Extraordinary Life: Love, Sex and Commitment" Embraces Healthy Sexual Behavior 3
... has announced,the appointment of Florence L. DiBenedetto as senior ... January 5, 2009, succeeding longtime,General Counsel Gary Loveridge who ... Formerly senior partner of the Sacramento-based law firm Hunter ... decades, DiBenedetto,served for more than 10 years as the ...
... Progressive Lenses and Transitions® Lenses to Produce Optimal Visual Experience ... ... Two of the most distinguished names in the optical industry are ... ,Carl Zeiss Vision, a leader for 160 years in precision optics, ...
... Dec. 17 Hologic, Inc. (Nasdaq: HOLX ), ... imaging systems and surgical products dedicated to serving the healthcare ... quarter fiscal 2009 operating results on Monday, February 2, 2009 ... host a conference call on Monday, February 2, 2009 at ...
... eggs to fertility clinics reported satisfaction with the process, ... 20 percent reported lasting psychological effects, according to the ... , The research by scientists at the University of ... 20 states and is the largest study to explore ...
... 1 Million Prescriptions , , ... wholly owned subsidiary of the Cystic Fibrosis Foundation, today announced ... cystic fibrosis (CF) community nationwide. , , ... patient, one prescription and a mission to improve access to ...
... to Meet Joint Commission Compliance through Patient Engagement , ... In an effort to improve patient safety and standards ... Patient Care (IPC) solutions, is enabling King,s Daughters Medical Center ... Patient Safety Goal (NPSG) 16 through GetWellNetwork,s interactive PatientLife ...
Cached Medicine News:Health News:Sutter Health Welcomes New General Counsel 2Health News:Carl Zeiss Vision and Transitions Optical Inc. Promote Pioneering Eyewear to Consumers 2Health News:Hologic, Inc. to Release First Quarter Fiscal 2009 Operating Results on Monday, February 2, 2009 2Health News:Most women report satisfaction with egg donation; some claim problems 2Health News:Most women report satisfaction with egg donation; some claim problems 3Health News:Cystic Fibrosis Services Pharmacy Celebrates 20th Anniversary 2Health News:King's Daughters Medical Center Leverages Unique Bedside Interactive Technology to Meet Requirements of Patient Safety Goal 16 2Health News:King's Daughters Medical Center Leverages Unique Bedside Interactive Technology to Meet Requirements of Patient Safety Goal 16 3
The 5539-7.5 linear transducer is a high frequency transducer dedicated to superficial and vascular imaging....
HST, versatile convex array abdominal transducer is multi-frequency, offering 5 levels of fundamental frequencies in addition to 4 settings of Harmonic frequencies. This transducer provides superb im...
Scan internal organs percutaneously while eliminating side lobe artifact....
... transducer is a curved ... the higher frequencies. Featuring ... this transducer provides exceptional ... frequency abdominal kidney bladder ...
Medicine Products: